Supplemental Material to Verhamme et al. "Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial" (Thromb Haemost 2016; 116.4) Suppl. 
Criteria for dose reduction
No criteria for dose reduction Figure 3 Suppl. Figure 1 : Kaplan-Meier cumulative event rates for recurrent venous thromboembolism and major plus nonmajor clinically relevant bleeding. Primary efficacy outcome (overall study period) and principal safety outcome (on treatment period) in patients with and without criteria for dose reduction.
